Cidara Therapeutics Presents New Promising Preclincal Data On Novel Dual-Acting Drug-Fc Conjugates At ESMO Immuno-Oncology Annual Congress
Portfolio Pulse from Benzinga Newsdesk
Cidara Therapeutics, Inc. (NASDAQ:CDTX) presented new preclinical data on its novel drug-Fc conjugates at the ESMO Immuno-Oncology Congress. The data showed that its CD73/PD-1 inhibitor DFC and CD73-targeting DFC, CBO421, exhibited robust anti-tumor activity in humanized mouse models of colorectal cancer. The CD73/PD-1 DFC demonstrated superior efficacy compared to monotherapies and is expected to file an IND application in mid-2024 for CBO421.
December 07, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cidara Therapeutics presented positive preclinical data for its CD73/PD-1 inhibitor DFC and CBO421, showing significant anti-tumor activity and outperforming monotherapies. The company plans to file an IND for CBO421 in mid-2024.
The positive preclinical data suggest potential for Cidara's drug candidates, which could lead to increased investor interest and a positive short-term impact on CDTX's stock price. The announcement of an upcoming IND filing for CBO421 further supports the potential for future development and commercialization, which is typically viewed favorably by investors. However, as these are preclinical results, the actual impact on the stock may be moderated by the recognition that clinical trials and regulatory approvals are still required before commercialization.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100